{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T13:46:51Z","timestamp":1776260811031,"version":"3.50.1"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2021,1,22]],"date-time":"2021-01-22T00:00:00Z","timestamp":1611273600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,1,22]],"date-time":"2021-01-22T00:00:00Z","timestamp":1611273600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"DOI":"10.1007\/s12185-021-03082-1","type":"journal-article","created":{"date-parts":[[2021,1,22]],"date-time":"2021-01-22T18:16:41Z","timestamp":1611339401000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Successful upfront cord blood transplantation for plasma cell leukemia in the first complete response after daratumumab therapy"],"prefix":"10.1007","author":[{"given":"Toshiyuki","family":"Ueno","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuhiro","family":"Sugio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takanori","family":"Ohta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasufumi","family":"Uehara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuju","family":"Ohno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,1,22]]},"reference":[{"key":"3082_CR1","doi-asserted-by":"publisher","first-page":"3724","DOI":"10.1182\/blood-2010-05-282632","volume":"116","author":"M Sant","year":"2010","unstructured":"Sant M, Allemani C, Tereanu C, De Angelis RD, Capocaccia R, Visser O, et al. Incidence of hematologic malignancies in Europe by morphologic subtype: results of the HAEMACARE project. Blood. 2010;116:3724\u201334.","journal-title":"Blood"},{"key":"3082_CR2","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1111\/j.1365-2141.1994.tb05114.x","volume":"88","author":"MA Dimopoulos","year":"1994","unstructured":"Dimopoulos MA, Palumbo A, Delasalle KB, Alexanian R. Primary plasma cell leukaemia. Br J Haematol. 1994;88:754\u20139.","journal-title":"Br J Haematol"},{"key":"3082_CR3","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1182\/blood-2014-03-565051","volume":"124","author":"WI Gonsalves","year":"2014","unstructured":"Gonsalves WI, Rajkumar SV, Go RS, Dispenzieri A, Gupta V, Singh PP, et al. Trends in survival of patients with primary plasma cell leukemia: a population-based analysis. Blood. 2014;124:907\u201312.","journal-title":"Blood"},{"key":"3082_CR4","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1038\/leu.2012.336","volume":"27","author":"C Fern\u00e1ndez de Larrea","year":"2013","unstructured":"Fern\u00e1ndez de Larrea C, Kyle RA, Durie BG, Ludwig H, Usmani S, Vesole DH, et al. Plasma cell leukemia: consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group. Leukemia. 2013;27:780\u201391.","journal-title":"Leukemia"},{"key":"3082_CR5","doi-asserted-by":"publisher","first-page":"2125","DOI":"10.1200\/JCO.2015.63.1929","volume":"34","author":"B Royer","year":"2016","unstructured":"Royer B, Minvielle S, Diouf M, Roussel M, Karlin L, Hulin C, et al. Bortezomib, doxorubicin, cyclophosphamide, dexamethasone induction followed by stem cell transplantation for primary plasma cell leukemia: a prospective Phase II study of the intergroupe francophone du my\u00e9lome. J Clin Oncol. 2016;34:2125\u201332.","journal-title":"J Clin Oncol"},{"key":"3082_CR6","doi-asserted-by":"publisher","first-page":"4612","DOI":"10.1182\/blood.V128.22.4612.4612","volume":"128","author":"B Royer","year":"2016","unstructured":"Royer B, Diouf M, Roussel M, Karlin L, Hulin C, Arnulf B, et al. Long term follow-up of hematopoietic stem cell transplantation (HSCT) for primary plasma cell leukemia (pPCL): final results of a prospective study of IFM group. Blood. 2016;128:4612.","journal-title":"Blood"},{"key":"3082_CR7","doi-asserted-by":"publisher","first-page":"e328","DOI":"10.1016\/j.bbmt.2020.08.035","volume":"26","author":"C Lemieux","year":"2020","unstructured":"Lemieux C, Johnston LJ, Lowsky R, Muffly LS, Craig JK, Shiraz P, et al. Outcomes with autologous or allogeneic stem cell transplantation in patients with plasma cell leukemia in the era of novel agents. Biol Blood Marrow Transplant. 2020;26:e328\u201332.","journal-title":"Biol Blood Marrow Transplant"},{"key":"3082_CR8","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1038\/leu.2011.312","volume":"26","author":"A Mahindra","year":"2012","unstructured":"Mahindra A, Kalaycio ME, Vela-Ojeda J, Vesole DH, Zhang M-J, Li P, et al. Hematopoietic cell transplantation for primary plasma cell leukemia: results from the Center for International Blood and Marrow Transplant Research. Leukemia. 2012;26:1091\u20137.","journal-title":"Leukemia"},{"key":"3082_CR9","doi-asserted-by":"publisher","first-page":"3338","DOI":"10.1038\/s41375-020-0830-0","volume":"34","author":"B Dhakal","year":"2020","unstructured":"Dhakal B, Patel S, Girnius S, Bachegowda L, Fraser R, Davila O, et al. Hematopoietic cell transplantation utilization and outcomes for primary plasma cell leukemia in the current era. Leukemia. 2020;34:3338\u201347.","journal-title":"Leukemia"},{"key":"3082_CR10","doi-asserted-by":"publisher","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","volume":"17","author":"S Kumar","year":"2016","unstructured":"Kumar S, Paiva B, Anderson KC, Durie B, Landgren O, Moreau P, et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016;17:e328\u201346.","journal-title":"Lancet Oncol"},{"key":"3082_CR11","doi-asserted-by":"publisher","first-page":"2900","DOI":"10.1200\/JCO.2016.69.2517","volume":"35","author":"J-J Lahuerta","year":"2017","unstructured":"Lahuerta J-J, Paiva B, Vidriales M-B, Cord\u00f3n L, Cedena M-T, Puig N, et al. Depth of response in multiple myeloma: a pooled analysis of three PETHEMA\/GEM clinical trials. J Clin Oncol. 2017;35:2900\u201310.","journal-title":"J Clin Oncol"},{"key":"3082_CR12","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1200\/JCO.19.01231","volume":"38","author":"B Paiva","year":"2020","unstructured":"Paiva B, Puig N, Cedena MT, Rosi\u00f1ol L, Cord\u00f3n L, Vidriales MB, et al. Measurable residual disease by next-generation flow cytometry in multiple myeloma. J Clin Oncol. 2020;38:784\u201392.","journal-title":"J Clin Oncol"},{"key":"3082_CR13","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1056\/NEJMoa1607751","volume":"375","author":"MA Dimopoulos","year":"2016","unstructured":"Dimopoulos MA, Oriol A, Nahi H, San-Miguel J, Bahlis NJ, Usmani SZ, et al. Daratumumab, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med. 2016;375:1319\u201331.","journal-title":"N Engl J Med"},{"key":"3082_CR14","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1111\/ejh.12986","volume":"100","author":"WI Gonsalves","year":"2018","unstructured":"Gonsalves WI, Buadi FK, Kumar S. Combination therapy incorporating Bcl-2 inhibition with Venetoclax for the treatment of refractory primary plasma cell leukemia with t (11;14). Eur J Haematol. 2018;100:215\u20137.","journal-title":"Eur J Haematol"},{"key":"3082_CR15","doi-asserted-by":"publisher","first-page":"E34","DOI":"10.1002\/ajh.25676","volume":"95","author":"S Nalghranyan","year":"2020","unstructured":"Nalghranyan S, Singh AP, Schinke C. The combination of venetoclax, daratumumab and dexamethasone for the treatment of refractory primary plasma cell leukemia. Am J Hematol. 2020;95:E34\u20135.","journal-title":"Am J Hematol"},{"key":"3082_CR16","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1182\/blood-2015-12-687749","volume":"128","author":"J Krejcik","year":"2016","unstructured":"Krejcik J, Casneuf T, Nijhof IS, Verbist B, Bald J, Plesner T, et al. Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma. Blood. 2016;128:384\u201394.","journal-title":"Blood"},{"key":"3082_CR17","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/j.clml.2020.01.010","volume":"20","author":"L Nikolaenko","year":"2020","unstructured":"Nikolaenko L, Chhabra S, Biran N, Chowdhury A, Hari PN, Krishnan A, et al. Graft-versus-host disease in multiple myeloma patients treated with daratumumab after allogeneic transplantation. Clin Lymphoma Myeloma Leuk. 2020;20:407\u201314.","journal-title":"Clin Lymphoma Myeloma Leuk"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-021-03082-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12185-021-03082-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-021-03082-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,22]],"date-time":"2021-01-22T18:34:40Z","timestamp":1611340480000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12185-021-03082-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,22]]},"references-count":17,"alternative-id":["3082"],"URL":"https:\/\/doi.org\/10.1007\/s12185-021-03082-1","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"value":"0925-5710","type":"print"},{"value":"1865-3774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,22]]},"assertion":[{"value":"14 November 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 January 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 January 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 January 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that there are no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}